Related Experiment Videos
[Turcot syndrome illustrated by two clinical cases].
P M Zink1, M Tatagiba, M Samii
1Neurochirurgische Klinik, Landeshauptstadt, Hannover.
Der Nervenarzt
|August 1, 1992
Summary
Turcot syndrome links familial polyposis coli (FPC) or sporadic polyposis with central nervous system (CNS) tumors. A modified classification helps differentiate cases, clarifying diagnosis for patients with CNS tumors and FPC history.
Area of Science:
- Genetics
- Oncology
- Neurology
Background:
- Turcot syndrome is characterized by the co-occurrence of colorectal polyposis and primary central nervous system (CNS) tumors.
- Intestinal manifestations include familial polyposis coli (FPC) or sporadic non-familial polyposis, histologically showing adenomas with potential adenocarcinomatous transformation.
Observation:
- Associated CNS tumors reported in Turcot syndrome encompass astrocytomas, glioblastomas, spongioblastomas, and medulloblastomas.
- A modified classification (ITOH's 1985) categorizes patients into four groups based on polyp count and family history.
- The study presents two cases, one in Group II (fewer than 10 polyps) and another in Group IV (CNS tumors or FPC with affected relatives).
Findings:
- The modified classification aims to refine the diagnostic criteria for Turcot syndrome.
- It is proposed that patients in the fourth group, despite having CNS tumors or FPC with affected relatives, should not be diagnosed with Turcot syndrome.
- The clinical presentation and pathological spectrum of Turcot syndrome are heterogeneous.
Implications:
- This classification modification may improve diagnostic accuracy and patient stratification for Turcot syndrome.
- Understanding the heterogeneity is crucial for accurate diagnosis and management of patients with polyposis and CNS tumors.
- Further research is warranted to validate the proposed classification and its clinical utility.